Metadata record for the article: The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

Summary This metadata record provides details of the data supporting the claims of the related article: “The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers”. The related study characterised the mutational, gene expression, pathway enrichment and tumour-infiltrating lymphocytes (TILs) dynamics across different timepoints of 35 HER2-negative primary breast cancer patients receiving neoadjuvant eribulin therapy (SOLTI-1007 NEOERIBULIN -NCT01669252). Subject of data: Homo sapiens Sample size: 35 Population characteristics: The stage I-II HER2-negative breast cancer patients were treated at the Vall Hebron Institute of Oncology, Barcelona during the years 2012 and 2013 in the open-label, single-arm SOLTI-1007 NEOERIBULIN phase II clinical trial (NCT01669252). Data access The whole exome sequencing bam files have been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under the study accession number https://identifiers.org/ega.study:EGAS00001004953 and dataset accession number https://identifiers.org/ega.dataset:EGAD00001006980. The decreased and increased pathway enrichment analyses are available in the files ‘decreased_pathway_enrichment_analysis.xlsx’ and ‘increased_pathway_enrichment_analysis.xlsx’, which can be accessed via GitHub at https://github.com/NeoVaCan/NPJBCANCER_DeMattos_2021/tree/main/Data_Supp_Table2.The supplementary tables of the related article are also available in Excel format as part of this figshare data record. The patient metadata are contained in the file ‘Patient metadata.xlsx’. Patient tumour-infiltrating lymphocytes data are contained in the file ‘Patient_TILsMeans_PAM50_ORR_HR_status_Neoprep_Maf.csv’. These files are not publicly available for the following reason: data contain information that could compromise research participant privacy. However, the data can be made available upon reasonable request to the corresponding author. Corresponding author(s) for this study Dr. Leticia De Mattos Arruda, IrsiCaixa, Germans Trias i Pujol University Hospital Germans Trias i Pujol Research Institute, Badalona, Spain, 08916. Phone: T [phone] (ext - 127) e-mail: [e-mail]. Study approval The Ethics Committee of the Vall Hebron University Hospital, Barcelona, Spain approved the study.